Wealthcreatures.com

Good ipo for listing Gains and also for Longterm

A Good ipo for listing gains and also for Longterm

SAKAR HEALTHCARE 🌟 HIGH-GROWTH PHARMA STORY TO WATCH NSE: SAKAR 🔥 Q1 FY27 — STRONG NUMBERS 📈 Revenue: ₹72.97 Cr | +38% YoY 📈 EBITDA: ₹21.25 Cr | +67% YoY 📈 PAT: ₹10.28 Cr | +120% YoY 💰 EBITDA Margin: ~29% 💊 THE BIG TRIGGER — ONCOLOGY ☑ Oncology becoming the core growth engine ☑ 55 oncology molecules developed ☑ 178 dossiers submitted globally ☑ 16 Marketing Authorisations received ☑ 65 oncology contracts executed ☑ Strong partnerships with Zydus, Accord, Intas, Torrent, Emcure & Glenmark ☑ EU-GMP approved Bavla Oncology Facility 🌍 EXPORT STORY JUST STARTING 🇪🇺 Europe & UK expansion 🌎 APAC • Africa • Latin America • CIS 📦 Increasing regulated-market exports 🤝 More dossiers → approvals → commercial launches 🚀 FUTURE GROWTH PLAN 🎯 FY27 Oncology Revenue Target: ~₹200 Cr 🎯 FY28 oncology revenue targeted at ~₹280–300 Cr 🎯 100+ approvals/registrations targeted 🎯 ₹500 Cr revenue milestone targeted over the next 2 years 🎯 Bavla facility potential: ₹800–1,000 Cr revenue at optimal utilisation over 4–5 years 🎯 Oncology EBITDA margin target: ~30%+ 💡 WHY SAKAR COULD BE INTERESTING Approvals + Oncology + Exports + Capacity Utilisation = Potential Operating Leverage The exciting part is that the capacity is already created — the next phase is converting approvals into commercial sales.

https://t.me/wealthcreature Link to Join

Top 3 pharma picks 🔥

Sakar Healthcare Fresh ATH 1200➕➕ 💚

Wockhardt pharma Another 5% 🆙 2200

Wockhardt pharma 2200 🔥

ESDS Software 20% 💥 🔥 🔐 UC

Sakar Healthcare Fresh ATH 1046 Looking Good for 1100-1200-1300-1400++ Longterm - 2000/2500/3000+

One of India’s most diversified pharmaceutical companies. PPL pharma ( Piramal Pharma) CMP - 214 Support @ 198-200 Strong 💪 support @ 177-180 zone Company shld do well in 12-24-36-48-60 months Longterm can be a big wealth creator Study 📚 it to get more confidence & than take your own decision 🔹Unlike many pharma companies that primarily manufacture and sell generic medicines, Piramal Pharma ( PPL )has built three powerful businesses under one roof: • Contract Development & Manufacturing (CDMO) • Hospital Generics • Consumer Healthcare Think of it this way 🔹When a global pharmaceutical company discovers a new drug, it doesn’t always manufacture it in-house. 🔹Instead, it partners with companies that already have world-class manufacturing facilities, regulatory approvals and scientific expertise. 🔹That’s exactly where Piramal Pharma comes in. 🔹The company helps global innovators develop and manufacture medicines while also selling critical hospital products and well-known consumer healthcare brands. Q1 FY27 Results Revenue: ₹2,270 Cr (+17% YoY) EBITDA: ₹284 Cr (+72% YoY) EBITDA Margin: 12.5% (expanded by nearly 400 bps YoY) 🔹The quarter was driven by healthy growth across all three businesses, with better capacity utilization, operating leverage and disciplined execution leading to a sharp improvement in profitability. 🔸What’s working for them? ✅ One of India’s leading global CDMO players serving innovator pharmaceutical companies. ✅ Manufacturing facilities across India, North America and Europe, giving it a truly global footprint. ✅ Strong position in complex hospital generics, including inhalation anaesthetics used by hospitals worldwide. ✅ Consumer healthcare business provides stable cash flows through established brands. 🔹Why do I like it? Mostly many investors value pharma companies based on the medicines they sell. 🔹But Piramal Pharma is different. It doesn’t just sell medicines. It helps develop them, manufacture them and deliver them to global pharmaceutical companies. 🔹That creates multiple growth engines instead of relying on a single therapy or product. 🔹As pharmaceutical outsourcing continues to grow globally, companies with strong manufacturing capabilities, regulatory approvals and long-standing customer relationships are likely to be among the biggest beneficiaries. Piramal Pharma remains one of the more interesting plays on India’s growing role in the global pharmaceutical supply chain.

PCPL OVERVIEW Main board IPO IPO OPENING FROM Monday 7th September to 9th September 🔹 Mumbai-based pure-play residential redevelopment developer 🔹 Focuses mainly on redevelopment of co-operative housing societies across Mumbai 🔹 Core presence across: • Borivali • Kandivali • Malad • Goregaon • Andheri • Vile Parle • Santacruz • Juhu • Bandra 🔹 Housing categories range from economical and mass-market homes to aspirational housing 🔹 C&W industry research ranked company No.1 in Western Suburbs by redevelopment unit supply between CY17-CY24 🔹 During CY17-CY24: • Redeveloped units: 1,503 • MCGM redevelopment projects: 27 • Share of units supplied by top 5 Western Suburb developers: ~30% 🔹 It also ranked No.1 across MCGM for redevelopment supply launched during CY21-CY24 Project portfolio As of Mar 31, 2026: 🔹 Completed: 28 projects • Developable area: ~14.2 lakh sq ft 🔹 Under construction: 20 projects • Developable area: ~16.3 lakh sq ft 🔹 Upcoming: 17 projects • Developable area: ~19.6 lakh sq ft 🔹 Total portfolio: 65 projects 🔹 Combined developable area: ~50.1 lakh sq ft 🔸 Portfolio expanded materially from 58 redevelopment projects reported at Dec 2024 Business model 🔹 Specialises in redevelopment rather than conventional large land-bank development 🔹 It takes over old housing societies, obtains approvals/FSI, constructs replacement homes for existing members and sells additional free-sale inventory 🔹 This reduces direct upfront land acquisition requirement compared with traditional real-estate development 🔹Debt repayment represents a meaningful part of fresh issue and can reduce future finance costs 🔹Pre-IPO promoter + promoter-group holding shown at ~63.35% Financials Breakup 🔹 Revenue: FY24: ₹449.75 cr FY25: ₹638.24 cr FY26: ₹763.93 cr 🔹 PAT: FY24: ₹39.62 cr FY25: ₹62.25 cr FY26: ₹71.32 cr 🔹 Assets: FY24: ₹966.80 cr FY25: ₹1,246.29 cr FY26: ₹1,799.19 cr 🔹 Revenue increased ~70% between FY24-FY26 🔹 PAT increased ~80% during same period Strengths - 🔹 No.1 redevelopment supply position in Mumbai Western Suburbs during CY17-CY24 🔹 Large pipeline of 65 completed, ongoing and upcoming redevelopment projects as of Mar 2026 🔹 Revenue increased from ~₹450 cr to ~₹764 cr in 2 years 🔹 PAT increased from ~₹40 cr to ~₹71 cr 🔹 FY26 ROCE of ~24% and ROE of ~34% 🔹 ₹223.75 cr of fresh capital is being directed towards redevelopment execution 🔹 ₹74 cr debt repayment can improve balance-sheet position and reduce finance burden My Take PCPL is a focused Mumbai redevelopment developer with a genuine leadership position in Western Suburbs and a ~50 lakh sq ft completed + ongoing + upcoming portfolio 🔹 Revenue, PAT and return ratios are strong, while IPO proceeds are largely directed towards redevelopment spending and debt reduction Disc - study before investing. All views are personal and only for Educational purpose . Consult your financial advisor before investing or Taking any position based on above Article

ESDS software Listed Today 112% 🆙 Next ipo coming with a bang 💥 issue opens on 7th Sept

A Must apply ipo for every Wealthcreatures member Apply in all your family members Account Longterm looks Good Company has very Good Track Record & very well know brand in Mumbai Revenue Growing PAT Growing Margin Expansion Future looks Great Study it I am applying for IPO 👍 Are You ?

Pranav Constructions (PCPL) is coming with main board IPO ISSUE OPENS - 7th Sept to 9th Sept 💰 IPO Details 🔹 Issue Size: ₹351.03 Cr 🔹 Fresh Issue: ₹315.60 Cr – 2.55 Cr Shares 🔹 OFS: ₹35.43 Cr – 28.57 Lakh Shares 🔹 Price Band: ₹118 – ₹124 per Share 🔹 Face Value: ₹10 🔹 Lot Size: 120 Shares 🔹 Minimum Retail Investment: ₹14,880 🔸Good Book 👍 Goldman Sachs is standout ▪︎ Goldman Sachs gets ~30% of the entire Anchor Book ▪︎ ~₹25 Cr allocation to Goldman ▪︎ ₹84.25 Cr Anchor Book ▪︎ ₹351 Cr Mainboard IPO 🔸Mukul Agarwal entity in anchor book 🔸PCPL is a leading Mumbai redevelopment-focused player. Goldman taking such a large share is notable for an IPO of this size. 🔸 Company is a leading pure-play Mumbai redevelopment player with Projects going on in major Mumbai premium market . 🔸 strong interest likely in subscriptions 🔸Project Pipeline and Execution & Scaling Redevelopment Projects: As of March 31, 2026, PCPL’s portfolio comprises 65 redevelopment projects across the Municipal Corporation of Greater Mumbai (MCGM) region. This includes 28 completed projects, 20 under-construction projects, and 17 upcoming projects, combining for a total developable area of 5.01 million square feet. 🔸Geographic Expansion and Brand Recall & Broadening Market Reach: PCPL has historically generated over 99% of its revenue from Mumbai’s Western Suburbs, a core pillar of its future growth includes expanding into alternative, highly lucrative sub-markets within the wider MCGM and MMR jurisdictions. 🔸Revenue from Operations: Grew from ₹447.48 crore in FY24 to ₹761.60 crore in FY26. Profit After Tax (PAT): Increased from ₹39.62 crore in FY24 to ₹71.32 crore in FY26. Operating Margins: Expanded from 13% to 17% over the past three fiscal years, driven by improved execution and pre-sale performance.